Extragonadal Germ Cell Tumours (EGGCTs)



Fig. 23.1
CT scan showing multiple left paraaortic and interaortico-caval LNs consistent with EGGCT. Teratoma was seen in most of them (Courtesy of Dr J-L Hoepffner, Onco-Urologist, Saint-Augustin Clinic and Bergonié Oncological Institute, Bordeaux, France)




  • The metastatic pattern of EGCCT also depends on the site and the histological type [4]:



    • Mediastinum: Seminomas to cervical LN and nonseminoma to lungs (27 %).


    • Retroperitoneum: Seminomas to retroperitoneal LN (26 %) and then to mediastinal and cervical LN. Nonseminomas to the lungs (49 %), abdominal LN (34 %) and liver (25 %). Metastases to the brain and bone have also been reported.





      23.1 Treatment of EGGCT






      • Retroperitoneal GCTs should be treated in a similar fashion as testicular tumours.



        • Seminomatous EGGCT: Cisplatin-based chemotherapy is the standard treatment and is credited for >90 % 5-year survival rate. Radiotherapy harbours a high rate of disease relapse; it carries a 5-year progression-free survival rate of 33 % compared with 87 % for chemotherapy [3]. Surgery is indicated if active residual masses are diagnosed, applying similar criteria as in testicular GCTs.


        • Nonseminomatous EGGCT: PEB chemotherapy has a median survival rate of 34 months. Surgery is indicated for residual masses or persistently high tumour markers (Fig. 23.2a, b).

          A331092_1_En_23_Fig2_HTML.gif


          Fig. 23.2
          (a, b) View of the retroperitoneum after an RPLND (same patient on Fig. 23.1) and the removed LNs (the forceps in Figure b reproduces the relative position of the aorta) (Courtesy of Dr J-L Hoepffner, Onco-Urologist, Saint-Augustin Clinic and Bergonié Oncological Institute, Bordeaux, France)


      • Mediastinal nonseminomatous EGGCTs have an overall 5-year survival rate of 45 and 17 % for intermediate- and poor-risk groups, respectively, defined as per the same IGCCCG criteria seen on Table 21.​3 [4]. A study recently performed at Indiana University suggests replacing bleomycin by ifosfamide for patients with mediastinal nonseminomatous EGGCTs to prevent pulmonary complications, as these patients generally require extensive thoracic surgical resection [9].
        < div class='tao-gold-member'>

        Only gold members can continue reading. Log In or Register to continue

      Stay updated, free articles. Join our Telegram channel

    • Jul 4, 2016 | Posted by in UROLOGY | Comments Off on Extragonadal Germ Cell Tumours (EGGCTs)

      Full access? Get Clinical Tree

      Get Clinical Tree app for offline access